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ABSTRACT 
Mitochondria are one of the central regulators of several physiological and pathological 
processes. For instance, homeostatic glycolysis, citric acid cycle, and oxidative 
phosphorylation are all regulated by mitochondria. In addition, these organelles play a pivotal 
role in apoptosis, a process of programmed cell death. In detail, the permeabilization of the 
outer mitochondrial membrane and the release of pro-apoptotic proteins from the 
intermembrane space are considered as an initiating and the no return step of apoptosis. 
Therefore, apoptosis induction and targeting mitochondria of cancer cells is a promising 
strategy for tumor cell elimination. During the studies of this PhD project mitochondria 
targeting and its consequences for cell death in neuroblastoma (NB) were investigated. 
In Paper I we demonstrated how low doses of the mitochondrial Complex II inhibitor 
thenoyltrifluoroacetone (TTFA) can sensitize a panel of chemoresistant NB cells for cisplatin 
treatment. Increase in cell death was due to TTFAs specific inhibition of the ubiquinone-
binding site of succinate dehydrogenase (SDH) that led to the formation of reactive oxygen 
species (ROS). Excessive ROS production resulted in the cytochrome c release from the 
intermembrane space of mitochondria and activation of apoptosis. However, the co-
administration of TTFA and cisplatin increased cell death only in NB cell lines with 
functionally active SDH. These results revealed how mitochondria targeting can be used to 
raise treatment efficacy, but previous testing of SDH activity is needed for successful outcome. 
Many of therapeutic drugs damage DNA, but their ability to target mitochondria is unknown. 
The effect of conventionally used chemotherapeutic drugs on mitochondria was tested in Paper 
II. Obtained results revealed etoposide-triggered suppression of Complex I respiration. 
Blockage of the electron chain led to the ROS formation, which did not induce apoptosis. 
However, cell death was detected after removal of glutamine, a precursor of the antioxidant 
glutathione. Therefore, etoposide also sensitizes mitochondria and can direct the mitochondrial 
membrane properties to apoptosis. 
Several tumors, such as NB, are dependent on glutamine and targeting glutamine metabolism 
offers a rationale for treatment improvement. The effect of glutamine withdrawal on anti-
cancer drug treatment of NB cells was studied in Paper III. We discovered a contrasting effect 
of drugs in glutamine deprived environment. Glutamine removal inhibited etoposide-induced, 
but significantly increased cisplatin-induced apoptosis, suggesting the activation of distinct 
mechanisms. Nevertheless, targeting glutamine metabolism could be considered as part of anti-
cancer therapy, but further studies to understand the mechanism of this finding are needed. 
Taken together, the findings of this PhD thesis have given new insights into mitochondria 
targeting for tumor cell elimination. We found new sensitizing effects of TTFA and etoposide 
that target respiratory chain complexes. Furthermore, the PhD project elucidated the role of 
glutamine metabolism in the outcome of NB treatment, which can be used as a basis for further 
studies.  
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1 INTRODUCTION 
1.1 CANCER 
Cancer is an “umbrella” term for a group of approximately 300 malignant diseases, which 
involve excessive cell growth and their potential capability to spread into surrounding tissue 
and organs. In comparison, benign tumors also have redundant cell division, but there is no 
invasion to other parts of the body. Generally, cancer “type” is named after the tissue of origin; 
however, the classification has become more specific. Every year about 14.1 million people 
and about 165,000 children under 15 years of age worldwide get cancer diagnosis and 
altogether 90.5 million people had cancer in 2015. Each year malignant growths cause about 
8.8 million deceased people, which corresponds to second leading cause of mortality and 
15.7% of all deaths.1-5 Therefore, malignant tumors are a burden to all human societies. 
There are several possible treatments for cancer, for example surgery, radiation-, chemo-, 
immune- and targeted therapies, and any combination of these. The outcome of the therapy 
depends on the tumor type and severity of the disease at the start of treatment. At the tissue 
level, cancer is a complex and heterogeneous disease, which makes a specific diagnosis and 
efficient treatment challenging. Five-year survival rate for developed world adult is 
approximately 66% and 80% in children under 15 at diagnosis.1,2,4,6 
Worldwide the most common type of cancer in males is lung cancer and in females breast 
cancer. Whereas, in children acute lymphoblastic leukemia and brain tumors prevail. Inherited 
genetic defects are responsible for approximately 5–10% of tumors.4,7 Due to better health care 
people live longer, but the risk of developing cancer rises considerably8. The possibility of 
cancer can be decreased by avoiding tobacco smoking9, alcohol10, and excessive body weight11. 
Other factors, such as infections12, UV radiation13, and pollutants13,14, are more difficult to 
control and can nevertheless introduce genetic changes in the cells. However, many genetic 
alterations are necessary to develop a malignant outgrowth3.  
Cancer development is a multistep process that occurs over a longer time period and involves 
several genetic mutations and dysfunctions of cellular programs, such as activation of 
oncogenes, cell proliferation, and inactivation of tumor-suppressor genes, immune system, 
DNA repair, and cell death in the pre-malignant cell. Development of metastasis, also known 
as spreading within the body, which meddles physiological functions and strains the tissue, is 
the main reason for malignancy-related deaths.3,15-17  
Hanahan and Weinberg have summarized the Hallmarks of Cancer that in detail describes the 
processes that regulate tumor initiation, development, and progression. These processes are 
allowing replicative immortality, supporting angiogenesis, refraining from growth suppressors, 
maintaining proliferative signalling, triggering invasion and metastasis, and avoiding cell 
death. Furthermore, appearing hallmarks are resisting immune destruction and unbalancing 
cellular energetics. Supporting characteristics are tumor-stimulating inflammation, and 
genome instability and mutation.3 
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Cancer in adults can be seen as an age-related spontaneous and/or environment caused disease, 
whereas early developmental defects are the main reason for childhood tumors18,19. Infant 
malignancies demonstrate an aggressive phenotype and are generally diagnosed at more 
progressed stages compared to adult disease. Furthermore, besides differences in paediatric and 
adult cancer development and diagnosis, there are also peculiarities in therapeutic approaches, 
effects, and consequences of therapy.20 For example, chemotherapy targets highly proliferating 
cells and since children’s bodies are actively growing, there are more severe side effects from 
anti-cancer drugs than in adults. The majority of side effects are temporary, but delayed growth, 
cognitive problems, and formation of secondary tumors later in life are the main issues in 
paediatric cancer treatment.21 
1.1.1 Neuroblastoma 
The most common extracranial solid cancer in childhood is neuroblastoma (NB), which 
originates from primitive cells of the sympathetic nervous system22. The leading initiators of 
NB development are defects in neural crest cells originating sympathoadrenal cells. The NB 
can develop anywhere in the sympathetic nervous system, but the main sites are in the abdomen 
along the sympathetic chain and in the adrenal gland medullary region.23 The NB has high 
genetic and biological heterogeneity and is, therefore, a complex disease that is under thorough 
investigation to better understand its origin and progression24,25. In Sweden, the prevalence of 
NB in children under 15 years is 0.7/100,000 and every year about 20 children are diagnosed 
with NB. Most of the incidences are diagnosed in infants under one year of age, who also have 
a good response to the treatment, whereas older patients have more severe outcomes. In 
addition, boys seem to be more affected than girls (M/F 1.22). Even though over 99% of 
localised tumors regress after therapy or recover spontaneously, overall survival rate five years 
after metastatic malignancy is still rather low ‒ 40%. Moreover, 15% of childhood cancer-
related mortality is caused by NB.22,23,26,27 
To improve NB risk assessment and diagnosis, several classification systems have been 
developed. For instance, the prognosis can be assigned by investigating the degree of 
differentiation, the status of stroma, and the mitosis-karyorrhexis index28. Even more precise 
diagnosis can be determined by considering NB stage, patient age, histologic category, grade 
of differentiation, MYCN oncogene status, chromosome 11q status, and DNA ploidy. These 
factors helps therapists to designate NBs into localized (L1 and L2) and metastatic disease (M 
and MS)29. 
Studies have identified several germline and sporadic genomic abnormalities in ALK 
(anaplastic lymphoma kinase)30, GALNT14 (polypeptide N-acetylgalactosaminyltransferase 
14)31, LIN28B (encoding lin 28 homolog B)32, MYCN33, and PHOX2B (paired-like homeobox 
2b) genes of NB patients34. In addition, excessive cell growth can be also supported by 
rearrangements in the TERT (encoded protein is telomerase reverse transcriptase)35,36 promoter 
(25% of the patients) and in the transcriptional regulator ATRX (encoded protein is RNA 
helicase) (10% of diagnosed children)37. Furthermore, almost all NBs have chromosomal copy 
number alterations, for instance, more than 50% have gain of 17q (ref. 38) and 30% have loss 
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of 1p36 and/or 11q1 (ref. 39). All mentioned chromosomal abnormalities are summarized in 
Table 1. 
Table 1. Frequency of germline and sporadic genomic rearrangements in NB40. Republished under CC BY 4.0. 
Gene or 
regioon 
Function of the 
encoded protein 
Modification Frequency (%) Reference 
ALK Receptor tyrosine 
kinase 
Mutation 
Amplification 
1 30,41 
MYCN Transcription factor Overexpression 
Amplification 
20 33,42,43 
LIN28B Suppressor of 
miRNA biogenesis 
Overexpression 
Amplification 
NA 32 
TERT Telomerase reverse 
transcriptase 
Rearrangements 25 35,36 
ATRX RNA helicase Rearrangements 10 37 
17q NA Gain 50 38 
1p36 NA Deletion 30 39 
11q1 NA Deletion 30 39 
 
About 2% of NBs have hereditary background and the first determined gene responsible for 
innate NB was ALK30,41. In addition, approximately 20% of NBs have amplification of the 
MYCN proto-oncogene, which is particularly prevalent in treatment resistant and poor outcome 
patients33,42,43. There have been attempts to discover even more NB driver mutations and genes 
by the help of whole-genome sequencing, but without great success37,44. Therefore, the main 
trigger of NB is MYCN amplification, and cancer aggressiveness is further maintained by other 
supporting mutations. Thus, the status of the MYCN gene amplification is examined as a 
compulsory step for therapy specification45.  
The MYCN gene was discovered in 1983 as a homologous amplification of the MYC gene and 
thereby belongs to the MYC family of regulators and proto-oncogenes. The MYC family 
proteins are transcription factors (MYC, MYCL, MYCN) that regulate several normal cellular 
processes like glycolysis, glutaminolysis, mitochondrial function and biogenesis33,46-48. 
Expression of the MYCN is tissue restricted and necessary for normal embryonic and postnatal 
development49. The MYCN gene is located on 2p24 locus, although when amplified, copies can 
be also found in other regions. Amplifications of the MYCN gene are identified as the inducers 
of tumor progression and proliferation.50,51 In addition, deregulation of MYC expression 
promotes apoptosis, although reduced p53 activity, overexpression of anti-apoptotic proteins, 
or downregulation of pro-apoptotic proteins inhibit the activation of controlled cell death52,53. 
Therefore, cancer progression is supported by MYC-driven proliferative signals and 
suppression of apoptosis. For studying MYCN‒induced NB formation and development in vivo, 
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several orthotopic, xenograft and also transgenic NB mouse models have been generated that 
overexpress MYCN in neural crest-derived cells to induce NB formation.54-59 
1.1.2 Neuroblastoma therapeutic approaches 
Low-risk NB patients, who are often less than 6 months old, have a better than 90% survival 
rate and this gives a possibility to identify the subgroups where lower doses of treatment can 
be used or therapeutics could be even avoided due to spontaneous regression60-62. In contrast, 
high-risk patients who are older and have MYCN amplification need more drastic approaches 
involving chemotherapy, surgery, radiotherapy, biologics (cis-retinoic acid) and 
immunotherapy63. The most commonly used regimen for NB treatment contains combinatory 
cycles of chemotherapeutic drugs, such as cisplatin, etoposide, vincristine, carboplatin, 
topotecan, and cyclophosphamide64-66. Following treatment also involves surgery and 
myeloablative therapy combined with stem cell and radiotherapy. Remaining cancer cells are 
targeted by retinoic acid, granulocyte macrophage colony stimulating factor (GM-CSF) and 
interleukin (IL)-2 to pursue differentiation.63,67-69 However, insufficient treatment, variety of 
side effects, individual variation of pharmacokinetic features and long-term toxicity are still a 
challenge. Therefore, novel ways to improve NB therapy are under investigation.  
One option is to directly target the MYCN protein. Normally, MYCN has relatively short half-
time, but amplification-caused high expression will increase the amount of active 
MYCN/MAX heterodimers. The dimerized complex can bind to the DNA and support 
continuous cancer progression as a transcriptional factor70. Thus, suppression of MYCN 
signalling could be used to stimulate apoptosis, neuronal differentiation and/or reduce 
proliferation71. For instance, MYCN downregulation by antisense oligonucleotides72 and 
RNAi73-75 has successfully decreased cellular proliferation, migration, and invasion. Described 
approach has been successful in vitro; however, clinical delivery of these compounds to the 
site of the tumor is still problematic71,76. Interestingly, there are also NB cell lines that exhibit 
a high level of MYCN mRNA or protein without the amplification of the gene itself. This effect 
can be caused by the overall disturbances in protein degradation, which does not require 
abnormalities in the MYCN gene.77,78 
Another approach for MYCN targeting is to block the heterodimerization of MYCN and MAX, 
which will lead to the homodimerization of unbound MAX and NB differentiation79. 
Compounds, such as 10058-F4 (ref. 80,81) and 10074-G5 (ref. 80), which block MYCN/MAX 
interaction, have demonstrated cell cycle arrest, apoptosis, differentiation, and improved 
efficacy of treatment was seen in vitro and in MYCN transgenic mice. In addition, drug-like 
molecules, such as JQ1 (ref. 82), OTX015 (ref. 83), or I-BET762 (ref. 84), have been developed 
to suppress bromodomain and transcription-regulating proteins and thereby prohibit MYCN 
transcription and NB cell growth in vivo. This approach can be beneficial for MYCN‒driven 
high-risk NB patients, but less toxic compounds need to be developed for clinical research. 
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1.2 CELL DEATH 
Excessive injury can be fatal to the cell, but depending on the cause and the severity of the 
damage, the cell tries to repair it or dies. Process of cell death was first described in 1842 by 
Carl Vogt. Since the initial discovery, different cell death modes and their associated 
morphological features have been identified and studied. However, for a long time cell death 
was considered to be only an accident and its regulatory processes remained unknown.85 
Thorough studies have revealed that cell death is an important and often regulated process that 
helps to maintain tissue homeostasis in multicellular animals. Programmed cell death prevents 
abnormal and malfunctioning cells from replicating in multicellular animals, thereby 
eliminating potential pathological conditions. Damaged or potentially harmful cells can be 
eliminated by different cell death modes after stimulation of specific cellular signaling.  
Historically cell death was divided into three major and morphologically distinct types: 
apoptosis (type I), autophagy (type II), and necrosis (type III). All these types are activated 
after unique signaling stimuli, which in turn activate type specific, sometimes overlapping, 
signaling pathways.86,87 Even though this morphological classification is still widely in use, 
several other controlled cell death modes have been described. For example, entotic cell death, 
ferroptosis, senescence, immunogenic cell death, mitochondrial permeability transition (MPT)-
driven necrosis, necroptosis, lysosome-dependent cell death, pyroptosis, parthanatos, and 
mitotic catastrophe88. These pathways are activated after specific signaling and also depend on 
cellular status. All of the pathways also demonstrate a substantial amount of interconnectivity 
and can result in an entire spectrum of morphological cell death features. 
The term apoptosis was first introduced in 1972 by John Kerr, Andrew Wyllie and Alastair 
Currie who broadened the terminology and thoroughly described this process. Development of 
multicellular organisms is dependent on apoptosis89,90. For example, forming of the limb digits 
and formation on neural tube of the central nervous system in higher vertebrate development 
are the result of apoptotic cell death91,92. Apoptosis is characterized by cell shrinkage, 
membrane blebbing, nuclear condensation and fragmentation that lead to the formation of 
apoptotic bodies, which will be thereafter engulfed and eliminated by macrophages.87 Further 
studies on the molecular mechanisms have revealed that apoptosis can be initiated either by a 
ligand binding to the cell-surface death receptor (the extrinsic pathway) or as a result of 
mitochondrial outer membrane permeabilization (MOMP) (the intrinsic pathway) (ref. 89,93).  
Autophagy is a catabolic “self-eating” process that is triggered in metabolic stress situations. 
For instance, starvation can initiate autophagy to supply the cell with metabolites. In some 
situations, it is more beneficial to extend survival by reducing and reusing some of the cellular 
content, instead of generating new nutrients. Another purpose of autophagy is to eliminate 
damaged organelles, protein aggregates and infecting organisms.94,95 There are three types of 
autophagy, such as microautophagy, Chaperone-mediated autophagy, and macroautophagy, 
which the last one is the most commonly addressed mechanism. During autophagy cytoplasmic 
macromolecules and specific organelles are covered with a double membrane to form a large 
intracellular autophagosome, which fuses with lysosomes to degrade the engulfed material96,97. 
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This process is thoroughly regulated by autophagy-related (ATG) proteins98. Furthermore, 
extensive autophagy can be related to cell death, but the mechanism and its purpose is still 
under investigation99-101. 
Necrotic cell death is usually considered a more passive mode of cell death that happens in 
extremely harsh conditions and ends with swelling, loss of plasma membrane integrity, and 
rupture of the dying cells. It will result in leakage of intracellular content into extracellular 
space, triggering the activation of the immune system. Recent developments in the necrosis 
fields have, however, discovered that necrosis can also be regulated by tumor necrosis factor 
(TNF)-α-mediated signalling, protein kinase RIP3, activated cell-surface receptors, DNA 
damage, or virus infection, which will cause the controlled process called necroptosis.102-104 
Furthermore, as well as apoptosis, necrosis plays a vital role in organism development and 
adult tissue homeostasis105,106. 
There is also a connection between the abnormalities in the described cell death modes, cancer 
development, and treatment resistance107. For example, apoptosis can be responsible for 
spontaneous tumor regression and is, hence, used as a strategy for cancer treatment; however, 
defects in apoptosis machinery can contribute to cancer formation and resistance to therapy3. 
In addition, autophagy can help cells to survive in lack of substrates and, thus, be beneficial for 
tumor progression108. Furthermore, necrosis-driven inflammation may promote cancer growth, 
but it can be also used to eliminate malignant cells109. Therefore, studies of these cell death 
modes help us to understand the underlying regulatory mechanisms and how they can be used 
for anti-tumor therapy. 
1.3 APOPTOTIC PATHWAYS 
Apoptosis is the most studied subject in cell biology110. Apoptotic cell death is an important 
part of multicellular organisms’ physiological and pathological processes. Cells undergoing 
apoptosis have very distinctive characteristics, such as aforementioned cell shrinkage, nuclear 
condensation and fragmentation, formation of apoptotic bodies etc.87,111 Apoptosis is a 
genetically controlled and evolutionarily conserved process, which is triggered by various 
signaling pathways when cellular damage is irreparable. As mentioned above, the two core 
apoptotic pathways, the extrinsic (death receptor) and the intrinsic (mitochondrial), are cross-
linked to increase the apoptotic signal and both of them lead to the activation of caspases 
(cysteine-aspartic proteases), key enzymes of apoptosis, that cleave proteins to stimulate cell 
death (Figure 1). Caspases are usually present in inactive pro-enzyme form and after activation 
or auto-cleavage can in turn activate other pro-caspases, resulting in protease cascade, 
amplification of the apoptotic signal and rapid cell death. 
Most of the caspases are pro-apoptotic, but several also take part of inflammatory processes 
(caspase-1, -4, -5, and -11)112 or are involved in keratinocyte differentiation (caspase-14)113. 
Some of the caspases are specific for other species, such as endoplasmic-specific apoptosis 
mediating caspase-12 (rodent specific)114, or bovine specific caspase-13115. There are two 
groups of apoptotic caspases – initiators (caspase-2, - 8, -9, and -10) and effectors (caspase-3, 
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-6, or -7). The initiator caspases, as the name requests, activate other complexes and effector 
caspases. The effector caspases, for example caspase-3, cleave anti-apoptotic proteins, such as 
inhibitor of caspase-activated DNase (ICAD)116 or B-cell lymphoma 2 (BCL-2)117, and cellular 
structures, such as lamins and cytoskeletal-regulatory proteins118. Caspase activity will result 
in activation of DNA fragmentation and shrinkage of the cell. Another important characteristic 
of apoptosis is the exposure of phosphatidylserine on the surface of the cell to attract 
macrophages that endocytose apoptotic cells.87,119,120 
 
Figure 1. Extrinsic and intrinsic pathways of apoptosis. ©2018 Novus Biologicals 
 
1.3.1 Intrinsic apoptotic pathways 
The intrinsic (mitochondrial) pathway of apoptosis is activated by intracellular signals, such as 
extensive DNA damage (cytotoxic drugs, defective DNA repair, irradiation, reactive oxygen 
species (ROS)), endoplasmic reticulum (ER) stress (unfolded protein response), hypoxia, 
hyperthermia, viral infections, and growth factor deprivation. For example, DNA damage-
induced apoptotic signals activate the tumor suppressor p53 that directs the signal via pro-
apoptotic proteins to the mitochondria. All the intracellular signals lead to the loss of the 
mitochondrial transmembrane potential (ΔΨm) and permeabilization of the outer 
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mitochondrial membrane (OMM) that results in the release of pro-apoptotic proteins from the 
intermembrane space to regulate and pursue apoptosis (Figure 1).89 
Some of these released proteins are: second mitochondrial activator of caspases (Smac)/direct 
inhibitors of apoptosis proteins (IAP) binding protein (DIABLO), apoptosis inducing factor 
(AIF), mammalian homolog of the bacterial high temperature requirement protein 
(HTRA2/Omi), Endonuclease G (EndoG), and cytochrome c. Release of cytochrome c, an 
important protein of the electron transport chain (ETC), from the mitochondrial intermembrane 
space to the cytoplasm is considered to be a key event in apoptosis induction. Free cytochrome 
c associates with the apoptotic protease activating factor-1 (Apaf-1), pro-caspase-9, and in 
presence of deoxyadenosine triphosphate (dATP) forms the apoptosome complex. This 
complex triggers caspase-9 that thereafter initiates effector caspases-3/-7. At the same time, 
Smac/DIABLO and HTRA2/Omi bind to the IAPs to block their inhibiting effect on caspase-
3/-7-/9.121-128 Furthermore, caspase activity also causes further damage to the mitochondria by 
cleaving Complex I and II subunits and triggering ROS production129. Taken together, pro- and 
anti-apoptotic proteins are in constant dynamic equilibrium, where minor damage to the 
mitochondria does not activate caspase cascade and apoptosis, but more severe injury will 
cause increase apoptotic caspases activity. 
The mitochondrial apoptotic pathway and permeabilization of the OMM can be regulated by 
BCL-2 family proteins that can be pro- and anti-apoptotic. Members of this family include 
BCL-2-associated X protein (BAX) and BCL-2 antagonist or killer (BAK) proteins that, upon 
intrinsic signal, oligomerize and form pores in the OMM to induce MOMP.130 Another way to 
initiate the caspase cascade is through ER stress mediated caspase-12 activation, which 
activates pro-caspase-9131. This pathway is operated in rodents and not in human cells. 
Furthermore, the mitochondrial pathway can also be activated independently of caspases when 
EndoG and/or AIF are released from the mitochondria. These proteins will move to the nucleus 
where they take part of chromatin condensation and fragmentation of the DNA (50-200Kb 
fragments)132,133. Nuclear AIF is responsible for fragmentation of DNA into large sections  and 
peripheral chromatin condensation134; and translocated EndoG cleaves nuclear chromatin123. 
Moreover, besides blocking IAPs activity, HTRA2/Omi has also protease activity and can 
degrade XIAP, cIAP1, cIAP2 and Apollon. This is also confirmed by lower apoptosis activity 
after decreased levels of HTRA2/Omi.135,136 In addition, the mitochondrial pathway can be 
indirectly activated by p53, which initiates the expression of the pro-apoptotic BCL-2 proteins, 
such as BH3 interacting-domain death agonist (BID), PUMA, and/or NOXA137-139. 
Furthermore, p53 can directly induce MOMP by activating BAX or BAK or by binding and 
inactivating anti-apoptotic BCL-2 proteins140,141. 
1.3.2 Extrinsic apoptotic pathways 
Extrinsic (receptor mediated) apoptosis is triggered when specific ligands bind to cell surface 
death receptors (DR). The DR family consists of 8 members, which belong to TNF receptor 
superfamily. These receptors have cysteine-rich extracellular domains and approximately 80 
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amino acid cytoplasmic “death domain” that transfers the extracellular death signal into 
intracellular.142 The most known DR is the tumor necrosis factor receptor 1 (TNFR1/DR1) that 
binds TNFα. In addition, CD95 (DR2/APO-1/Fas) binds CD95L and TNF-related apoptosis-
inducing ligand receptors 1 and 2 (TRAILR1/TRAILR2; also DR4/DR5) binds TRAIL.143,144  
The biophysical status of the ligand can also regulate the outcome of the intracellular signal. 
For instance, TNR-R1 binding to the soluble TNFα activates the NF-κB pathway but binding 
to membrane-displayed TNFα activates the extrinsic apoptotic pathway145,146. After ligand 
binding, receptors form trimeric homo-oligomers and recruit death domain-containing protein 
(Fas-Associated Death Domain (FADD) or TNFR-associated death domain protein (TRADD)) 
and pro-caspase-8/-10 to form death-inducing signalling complex (DISC). Pro-caspase-8 is a 
monomeric cytoplasmic protein and forms the dimeric confirmation only after recruitment to 
the DISC. As part of the DISC, pro-caspase-8 undergoes auto-proteolytic cleavage that triggers 
its catalytic activity, which in turn activates effector capases-3/-7, to perform cell death.147-151 
The scheme describing the extrinsic apoptotic pathways is illustrated in Figure 1. 
Extrinsic apoptosis can be divided into two prototypic cell types. Type I cells have sufficient 
caspase-8 activation to directly activate downstream effector caspases, whereas type II cells 
have less DISC-activated caspase-8 and cell death signal is amplified through intrinsic 
mitochondrial pathway.152 More specifically, in addition to the cleavage of effector caspases, 
caspase-8 can cleave the pro-apoptotic protein BID, which truncated form (tBID) assists to 
oligomerize pro-apoptotic proteins BAX and BAK to form pores in the OMM. After pore 
establishment, proteins from the mitochondrial intermembrane space are released into the 
cytosol and mitochondrial apoptosis pathway is activated. Thus, the external apoptotic signal 
can be amplified by mitochondrial pathway.87,152  
Caspase-8 activation can be regulated by the FADD-like interleukin-1β–converting enzyme 
(FLICE)-like inhibitory protein (FLIP) that, due to structural similarity, can replace caspase-8 
in the DISC complex and inhibit apoptotic activity.153 The main caspase-8 activity regulator is 
cFLIP that has two primary mRNA splice variants, cFLIPL (long) and cFLIPS (short), which 
can both dimerize with caspase-8/-10 and/or DISC. However, the role of cFLIP isoforms is not 
clear and complicated balance between the variants and the pro-caspase-8 seems to determine 
the outcome of the signaling.154-156 
1.3.3 Perforin/granzyme B apoptotic pathway 
The perforin/granzyme B apoptotic pathway is mediated by cytotoxic T-cells (CTLs), which 
release the pore-forming perforin and cytoplasmic granules containing serine protease 
granzyme B. Secreted perforin forms transmembrane pores that allow granules into cytoplasm. 
Granules contain granzymes, such as granzyme A and B, that upon release can cleave over 300 
apoptosis triggering and supporting substrates, including BID, ICAD, initiator caspase-8 and -
10, and executioner caspase-3 and -7.157-160 Furthermore, granzyme B increases the 
mitochondrial ROS levels that contributes to the cell death activation, target nuclear PARP and 
DNA PK proteins, and extracellular matrix proteins157,161. Altogether, this described caspase-
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independent apoptotic pathway is facilitating elimination of tumor cells and virus infections, 
which often suppress caspase activity and apoptosis162.  
1.3.4 Apoptosis and cancer 
The majority of anti-tumor drugs initiate the intrinsic apoptotic pathway. However, one of the 
reasons of therapy resistance are frequent mutations in mitochondrial apoptosis pathway genes. 
For example, mutations in the p53 are the most prevalent in human malignancies, detected in 
80% of tumor cell lines and 40% of human cancers163, and thereby also affect activity of the 
intrinsic apoptotic pathway. In addition, translocation and overexpression of the BCL-2 
oncogene is associated with about 85% of human follicular lymphomas164. Moreover, somatic 
mutations in the BAX gene, such as single nucleotide substitutions or frameshift mutations, 
have been identified in solid and hematological malignancies165,166.  
In addition, cancer cells have high levels of pro-apoptotic proteins; although, their activation is 
inhibited in several ways. For instance, intrinsic apoptosis can be suppressed by overexpression 
of IAPs.167 Therefore, suppressing IAPs is a promising way to selectively target tumor cells. 
For example, overexpression of Smac/DIABLO or administration of IAP-binding peptides, 
such as Smac-N7, can sensitize cells for treatment168-170. However, IAPs do not seem to be the 
main regulators of apoptosis induction. Another way to regulate apoptotic proteins is on the 
transcriptional or post-transcriptional level. For instance, anti-apoptotic BCL-2 family proteins 
are transcriptionally regulated by nuclear factor kappa-light-chain-enhancer of activated B cells 
(NF-κB)171. 
Cancer cells have also developed several strategies to defeat extrinsic apoptotic signals. Mostly 
cell death is avoided by an increase in anti-apoptotic molecules or by a decrease or defective 
function in pro-apoptotic proteins. For instance, tumor cells can have mutations in the receptor 
gene 172-174, downregulate the expression on the cell surface death receptors 175, prevent receptor 
transportation from ER to the cell surface 176, or express decoy receptors 177. In addition, death 
receptor signaling in tumor cells can also be prevented by affecting the activity of their 
cytoplasmic domains. One of these regulators is aforementioned caspase-8 inhibitory protein 
FLIP, which is highly expressed in many cancer cells156,178,179. 
Numerous chemotherapeutic drugs induce CD95L expression and extrinsic cell death via 
CD95 receptor180-182. This is a p53-independent process and is especially helpful for patients 
with deleted/mutated/inactivated p53183. However, CD95L and TNFα have shown serious side 
effects and, therefore, their clinical use is questionable184, whereas TRAIL has been more 
promising candidate185,186. The synergistic effect of TRAIL and chemotherapeutic drugs results 
in a downregulation of anti-apoptotic proteins187 and upregulation of pro-apoptotic 
molecules188, which altogether leads to the activation of both the intrinsic and extrinsic 
apoptotic pathway. 
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1.4 MITOCHONDRIA AND CANCER 
Mitochondria are known as the powerhouses of the cell, but they are also crucial for normal 
cell function by regulating overall homeostasis. Cells have hundreds of mitochondria, which 
can be a mixture of wild-type and damaged organelles. Mitochondria have a 16Kb DNA 
genome (mtDNA) that encodes certain respiratory proteins. However, due to co-evolution, 
most mitochondrial proteins are nuclear encoded. The role of mutations of the mtDNA are less 
distinct and, unfortunately, quite often sequencing studies do not include the mtDNA. 
Nonetheless, relatively low mutation rate has been found in cancer mtDNA, indicating to a 
regulative mechanism involved in mitochondrial quality control to support cellular metabolism. 
For example, defects in autophagy cause impaired mitochondrial activity and increase cell 
death189-191. Thus, autophagy works as a quality control, removing damaged organelles, but 
also provides cells with metabolic substrates and aids malignant growth191,192. 
Besides mitochondria role in energy production and apoptosis, these organelles also regulate 
metabolic cell signaling, lipid homeostasis, steroid and heme synthesis, and cytosolic calcium 
ions (Ca2+) homeostasis.193-195 More specifically, mitochondrial citric acid/Krebs/tricarboxylic 
acid cycle (TCA cycle) produces nicotinamide adenine dinucleotides (NADH) and flavin 
adenine dinucleotides (FADH2) that donate electrons to the ETC. Electron flow through the 
ETC produces a proton gradient on the inner mitochondrial membrane (IMM). This proton 
gradient is used by the ATP synthase to produce ATP. However, the electron flow through 
ETC also generates ROS, which are involved in regulation of various metabolic reactions, 
including MAP kinase and HIF transduction pathways196,197 and can even lead to cell death. 
Furthermore, as mentioned above, OMM related BCL-2 family proteins regulate apoptosis, 
when pro-apoptotic proteins BAX and BAK form channels that aid the release of cytochrome 
c from the mitochondrial inter membrane space198,199. Therefore, the interaction between the 
cell and the mitochondria regulates wide range of cellular functions, such as metabolism, 
growth, and survival. 
Mitochondrial dysfunction can lead to various illnesses, including type 2 diabetes, 
neurodegenerative diseases, and cancer3,200,201. These disorders may be caused by maternally 
inherited defective mitochondrial genome or mutations in nuclearly encoded mitochondrial 
proteins. One of the deregulators of this organelle is proto-oncogene MYC, which is known to 
regulate cellular metabolism and mitochondrial function202,203. While this organelle can cause 
or be part of many pathologies, they are also seen as potential targets for therapy. For example, 
several tumor therapeutics destabilize mitochondria to activate apoptosis. 
1.4.1 BCL-2 family 
BCL-2 family consists of over 20 proteins, which are either pro- or anti-apoptotic and divided 
into groups depending of their arrangement of up to four different BCL-2 homology (BH) 
domains204,205. The balance between these proteins will determine cell survival or apoptosis. 
For instance, anti-apoptotic proteins BCL-2, BCL-xL, and myeloid cell leukemia (MCL)-1 that 
contain all four variants of the BH domains obstruct MOMP by binding and prohibiting pro-
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apoptotic proteins. Apoptosis supporting BCL-2 family proteins consist of BH-3 only and 
BH1-3 containing effector proteins. The BH-3 only proteins (BID, BAD, BIM, NOXA, 
PUMA) react to intracellular cell death stimuli, such as DNA damage or ER stress, and are 
activated in diverse ways. For example, PUMA and NOXA by transcriptional upregulation, 
BAD by posttranslational modifications, and BID by proteolytic cleavage. Regardless of their 
activation mechanism, these pro-apoptotic proteins suppress anti-apoptotic BCL-2 proteins 
activity. In addition, the BH-3 only proteins trigger the effector proteins (BAK, BAX) to form 
OMM pores, which release cytochrome c from the intermembrane space and activate 
apoptosis.198,204,206 The classification on BCL-2 proteins is summarized in Figure 2. 
 
Figure 2. Classifications of BCL-2 proteins according to conserved BCL-2 homology (BH) domains. 
Abbreviation: TM, transmembrane domain.207 
 
Usually is BAX located in the cytosol and BAK, together with the other BCL-2 proteins, 
connected to the OMM by its carboxy-terminal anchor208. There are several ways how BAX 
and BAK may be activated. For instance, after apoptotic stimuli constantly active BAX/BAK 
lose their association with the anti-apoptotic proteins (BCL-2, BCL-xL, MCL-1)209-211. 
Another model suggests that BAX/BAK need direct activation via N-terminal conformational 
change by the BH-3 only proteins tBID and BIM212,213. In addition, activation by the interaction 
with the mitochondrial lipid bilayer is also suggested. It is proposed that tBID inserts into the 
OMM and recruits BAX, which enrolls more BAX to undergo oligomerization and MOMP214-
216. In conclusion, the balance between the BCL-2 family pro- and anti-apoptotic proteins 
regulates MOMP induction. 
Usually NB does not have mutations in BCL-2 but its overexpression and dysregulation are 
common217-219. Moreover, a link between MYC and BCL-2 expression has been discovered. 
The MYC overexpression frequently occurs together with mutations in BCL-2 genes that assist 
proliferation and decrease apoptosis.220,221 Thus, drugs affecting the equilibrium between pro- 
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and anti-apoptotic proteins are studied for treatment improvement. This can be achieved by 
using anti-cancer drugs in combination with inhibitors of anti-apoptotic BCL-2 proteins (e.g. 
ABT-199), which are structurally or functionally similar to BH3-only proteins222,223. However, 
modest outcome, side effects222, and resistance in relapsed NBs224 make this approach 
challenging. These drawbacks are due to suppression of apoptosis by the compensatory 
upregulation of the anti-apoptotic MCL-1 protein. This can be avoided when ABT-199 is used 
simultaneously with MCL-1 inhibitor (e.g., A-1210477), which will cause NB cell death225. 
Another way is to directly activate BAX oligomerization with a small molecule BAM7 to 
promote MOMP and to make cells more sensitive to treatment226. 
1.4.2 Mitochondrial permeability transition pore (MPTP) 
Release of mitochondrial content, such as pro-apoptotic proteins like cytochrome c or AIF, into 
the cytosol can be also induced through mitochondrial permeability transition pore (MPTP), a 
non-specific Ca2+-dependent and ROS sensitive pore in the IMM. Opening of this pore leads 
to mitochondrial osmotic swelling, vanishing of their ΔΨm, and breaking of the OMM.227,228 
The main MPTP components are voltage-dependent anion channel (VDAC), adenine 
nucleotide translocase (ANT), and cyclophilin D; however, it is not fully clear which other 
proteins are involved in the pore formation229,230. For instance, ATP synthase F0 (ref. 231) 
subunit c and phosphate carrier (PiC)232 can also take part of the pore formation. The function 
of MPT in apoptosis is still not clear but it is suggested that not all of the mitochondria are 
subjected to MPT and recovery from the damage is possible233.  
Inducing MPTP formation is also considered as a potential strategy to activate apoptosis in 
tumor cells with high level of anti-apoptotic proteins. For example, MPT can be induced by 
depleting its endogenous inhibitors, such as glucose, ATP, glutathione (GSH), or creatine 
phosphate. Another attractive strategy is to use drugs that stimulate ROS production, increase 
intracellular Ca2+ concentrations, or induce detachment of hexokinase (HK) from mitochondria 
to consequently activate MPT.229,234,235 There are also several drugs that directly affect MPT 
pore. Ligands that bind to ANT, such as ANT-cross linker 4-(N-(S-glutathionylacetyl) amino) 
phenylarsenoxide (GSAO), and inhibit its ATP/ADP antiporter activity induce tumor cell 
death236. The MPT is also promoted by retinoic acid derivatives, for instance all-trans-retinoic 
acid or ST1926, that are besides that supporting differentiation of NB and leukaemia. Their 
main mechanism is to increase cytosolic calcium levels for MPT induction.237,238 Furthermore, 
regulating the actions of the MTP pore-interacting peripheral benzodiazepine receptor (PBR), 
which is often overexpressed in cancers, may have anti-tumor effects. The PBR is also 
suppressing BCL-2 anti-apoptotic proteins and affecting this interaction can activate both types 
of OMM permeabilization. This has been demonstrated by PBR ligands PK11195 and RO5-
4864 that sensitize tumor cells to chemotherapeutic drugs-induced cell death.239-241 
1.4.3 Electron transport chain (ETC) 
Mitochondrial ETC consists of four enzyme complexes (I, II, III, and IV) that are located in 
IMM together with cytochrome c and ATP synthase (Complex V) (Figure 3). These proteins 
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are responsible for electron transfer from TCA substrates to oxygen. Complex I (NADH 
ubiquinone reductase) accepts and transfers electrons from NADH and Complex II (succinate 
dehydrogenase) gets electrons from succinate, through FADH2. Thereafter, both of these 
complexes donate their electrons to Complex III (Ubiquinol-cytochrome c reductase), which 
transfers these via cytochrome c to Complex IV (cytochrome c oxidase) and then oxygen to 
form water. Described electron movement results in transportation of protons from the matrix 
to the intermembrane space of mitochondria causing the formation of the mitochondrial 
membrane potential. This electrochemical gradient is finally used to produce ATP from ADP 
by transporting protons back to the mitochondrial matrix by ATP synthase.242-244 
 
Figure 3. Mitochondrial electron transport chain and oxidative phosphorylation. Republished from "Oxidative 
phosphorylation: Figure 3," by Openstax College, Biology (CC BY 3.0). 
 
Cancer cells are rapidly dividing, which can make them hypoxic and change their energy 
supply from OXPHOS to glycolysis. Furthermore, tumor cells have a tendency to have lower 
amount of mitochondria and/or abnormalities in OXPHOS genes245-247. On the other hand, 
relapsing cancer cells have demonstrated elevated levels of OXPHOS248-250. For example, 
MYC can induce the expression of mitochondrial complexes and support respiration47,251. 
Described changing of the metabolic organization of the cell assists them to survive in poor 
nourishment environment. Thus, resistant tumor cells may be eliminated by combined use of 
chemotherapeutic drugs and ETC inhibitors. Cell death caused by excessive ROS production 
has been shown to derive mostly from Complex I and III, but there is also evidence 
demonstrating ROS production from Complex II252-255.  
There are numerous Complex I inhibitors out of which rotenone is the most common 
example256. However, acute neurotoxicity as a side effect is reducing their potential use for 
treatment257. On the other hand, inhibiting Complex I by metformin or tamoxifen258-260 or 
blocking Complex II by α-tocopheryl succinate (α-TOS) or thenoyltrifluoroacetone 
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(TTFA)261,262 to promote electron leakage and ROS formation are used to improve outcome of 
the therapy. For example, TTFA attaches to the Complex II ubiquinone (UbQ)-binding site to 
suppress electron flow, resulting in electron escape and ROS formation263. In addition, using 
non-toxic doses of TTFA and cytotoxic drugs in combination can induce ROS production and 
thereby improve the treatment outcome in NB cell lines262.  
Complex III that accommodates electrons form both Complex I and II is also known as 
coenzyme Q: cytochrome c – oxidoreductase and can be inhibited by antimycin A to increase 
ROS production and inhibit anti-apoptotic proteins in tumor cells264-266. Furthermore, 
successful results from xenograft models and clinical trials with resveratrol267 and benzyl 
isothiocyanate (BITC)268 show a clear potential for Complex III blockers as tumor eliminating 
drugs. Complex IV is mostly inhibited by transcriptional regulation by fenretinide269 or 
doxorubicin270. In addition, apoptotic cell death via ATP synthase blocking may be facilitated 
by oligomycin271 or 3,30-diindolylmethane (DIM)272. The DIM has shown to also have cell 
cycle, angiogenesis inhibition and pro-apoptotic activity abilities273, which are now tested in 
clinical trials. 
1.5 OXIDATIVE STRESS AND CANCER 
Oxidative stress is caused by an imbalance between ROS production and the ability of cells to 
take care of the free radicals or to repair the damage. Some of the most known free radicals are 
superoxide anions (O2-), hydroxyl (OH•), hydrogen peroxide (H2O2), and peroxyl radicals 
(HO2)274. ROS production is mainly located in the mitochondria and it is considered to be a 
normal cellular process that takes place during oxygen metabolism. It is caused by 
imperfections in the ETC electron flow, where the leakage of electros from complex I and III 
forms ROS. Other sources of internal ROS are peroxisomes, enzymes, xanthine oxidase, and 
the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase complexes. These free 
radicals participate in normal physiological cell signalling to regulate proliferation, 
differentiation, and cell survival. Most of the ROS is produced in the mitochondria, whereas 
external ROS is usually induced by UV radiation or chemical compounds. Excessive amount 
of ROS can cause damage to the cells and generate “secondary” ROS by interacting with other 
compounds and cause severe cell damage.275-278  
There are several cellular defence systems that are responsible for ROS elimination and 
regulation. Oxidative damage can be avoided by preventing the formation of ROS or by using 
enzymatic or non-enzymatic antioxidants to neutralize the radicals. The most known 
antioxidants are dietary antioxidants (e.g. vitamins A, C, and E), endogenous antioxidant 
enzymes (e.g. superoxide dismutase (SOD), catalase (CAT), GSH peroxidase (GPx), GSH 
reductase (GR), and peroxiredoxins), and antioxidant molecules (e.g. GSH), coenzyme Q, 
ferritin, and bilirubin).279  
Abnormal levels of cellular antioxidants, such as decrease in GSH, a three amino acid thiol 
protein consisting of glutamine, cysteine, and glycine, makes cells more sensitive to oxidative 
stress and induce oxidative damage on lipids, DNA, and proteins. ROS mediated damage is 
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associated with various illnesses involving neurodegenerative and age-related metabolic 
disorders, inflammatory disease, cardiovascular disease, allergies, immune system 
dysfunctions, diabetes, and cancer. For example, cancer initiation and development are 
connected to ROS-induced DNA mutation and damage, genome instability, angiogenesis, and 
proliferation. Tumor cells with already elevated ROS levels also have an increase in GSH 
formation and GSH S-transferases (GSTs) to enhance their resistance to free radicals. In 
addition, circulating tumor cells seem to have increased supply of NADPH to cope metastatic 
stress induced increase of ROS. Moreover, introducing antioxidants to high ROS producing 
cells can stimulate metastasis, instead of prevention. Malignant tumors sustain cellular ROS 
level that is supporting proliferation without inducing cytotoxicity. Different ROS levels can 
cause distinct outcome based on the cells, tissues, ROS production site and concentration. 
Furthermore, excessive ROS production in cancer cells can be in turn used to increase the 
efficiency of the treatment by using ROS activated pro-drugs that induce apoptosis.280-286 
Furthermore, keeping in mind the importance of GSH in induction and development of tumors, 
blocking the GSH-dependent defense system is another promising approach for anti-cancer 
therapy286. The GSH protects proteins by being oxidized into GSH disulphide (GSSG) by 
reducing cysteine disulphide bonds. The GSSG is in turn reduced by GSH reductase back into 
GSH.287 Studies using buthionine sulfoximine (BSO) to block GSH synthesis have shown 
promising results by inhibiting the formation of several cancers (e.g. lymphomas, sarcomas, 
and breast tumors). Unfortunately, this approach does not work with metastasized cancers, 
which have upregulation of thioredoxin (Trx) to compensate the lack of GSH. However, in 
some tumors where BSO is used together with melphalan, synergistic effects can be seen.288-
290 Targeting other mitochondrial redox regulating mechanisms has been also successful. For 
example, the amount of ROS can be increased by inhibiting glutamate dehydrogenase 1 
(GDH1) to reduce fumarate levels and thereby decrease antioxidant GPx291, which normally 
reacts with H2O2 and organic hydroperoxides.  
1.6 METABOLISM AND CANCER 
The extensive proliferation of the cancer cells also increases their biosynthetic demands, which 
raises their need for higher uptake of nutrients from the environment. There are two main 
substrates of energy in mammalian cells – glucose and glutamine. These substrates are 
catabolized to provide cells with carbon intermediates for macromolecule formation. One 
hallmark of cancer is metabolic reprogramming that supports tumor cell macromolecule 
synthesis, energy requirement, and survival292. As previously described, normal cells acquire 
most of the ATP from OXPHOS (Figure 4a), whereas in tumors, as a direct and/or indirect 
consequence of oncogenic mutations, mitochondrial metabolic reactions are changed. For 
example, tumors direct glycolytic intermediates instead of mitochondrial oxidation to pentose 
phosphate pathway (PPP), serine biosynthesis, and lipid biosynthesis. Furthermore, the PPP 
produced NADPH is used to reduce oxidative stress, mitochondrial ROS production, and 
support survival in fluctuating oxygen conditions.293-295 
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This is accomplished by restricting glycolytic enzyme activity296 or glycolysis end-product 
pyruvate consumption by mitochondria297. Furthermore, instead of pyruvate, tumor cell TCA 
cycle is supported by upregulated glutaminolysis, fatty and amino acids, at the same time 
maintaining aerobic glycolysis (Figure 4b,c) (ref. 297-299). This is a clear example how cancer 
cells are able to change their metabolism to meet their needs. These hyperglycolytic cells can 
be targeted by inhibition of glycolytic pathway. For instance, suppressing ATP citrate lyase, 
lactate dehydrogenase A, or acetyl-CoA carboxylase and fatty acid synthase will all result in 
decreased tumor growth. Therefore, targeting metabolic enzymes could effectively attenuate 
cancer development. However, not all of the tumors possess this phenotype and instead produce 
ATP through OXPHOS pathway. This makes targeting their metabolism challenging and 
inhibition of glycolysis together with mitochondrial respiration would be more efficient.293,294 
 
Figure 4. Normal and cancer cell metabolic phenotypes. Abbreviations: glucose (GLUC), lactate (LAC), pentose 
phosphate pathway (PPP), pyruvate (PYR), citrate (CIT), α-ketoglutarate (AKG), glutamine (GLN), malate 
(MAL).300 Republished under CC BY-NC-SA. 
 
1.6.1 Glucose dependency 
The aforementioned cancer cells glucose dependency was discovered by Otto Warburg. These 
changes are even seen in aerobic conditions, despite resulting in less ATP than from OXPHOS 
(2 vs 36), because ATP production through aerobic glycolysis is quicker than in 
OXPHOS.301,302 This metabolic change makes cells less dependent on oxygen and helps them 
to survive in hypoxic environment303. The phenomenon of high glucose uptake by cancer cells 
is also nowadays widely used in clinics for tumor imaging by fluorodeoxyglucose positron-
emission tomography (FDG-PET)304. 
Normally pyruvate is metabolized in mitochondria by pyruvate dehydrogenase (PDH) to 
support TCA and OXPHOS. Whereas in cancer cells PDH activity is suppressed resulting in 
decreased OXPHOS and pyruvate conversion to lactate by lactate dehydrogenase (LDH). 
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However, aerobic glycolysis is not prevalent in all tumors and now it is known that 
mitochondrial respiration defects are not causing the effect, because most cancers actually 
maintain mitochondrial function and respiration, which are regulated by strict cellular 
signaling305. These metabolic modifications are conducted by oncogenes/tumor suppressor 
genes that are also responsible for proliferation upregulation, such as p53, MYC and hypoxia-
inducible factor 1 (HIF-1)306,307.  
The MYC oncogene stimulates glucose import (e.g. GLUT1), glycolysis (e.g. HK2, PDK1), 
and mitochondrial biogenesis to provide cancer cell with metabolic intermediates that are 
needed for excessive cell growth308-310. These tumor cell peculiarities make them also more 
vulnerable for glucose transportation and glycolysis specific targeting311,312. One possible 
approach is to target HK2 activity. For instance, the synthetic analogue of glucose 2-deoxy-D-
glucose (2-DG) cannot be metabolized after phosphorylation by HK2, which causes 2-DG-6-
P accumulation, leading to the inhibition of glycolysis and cancer growth313-315. Tumor 
elimination by 2-DG has been demonstrated in numerous NB cell lines316 and xenograft 
models317, irrespectively of cancers MYCN expression, suggesting promising clinical 
significance. Moreover, the clinical outcome of the 2-DG treatment is improved when co-
treated with cytotoxic drugs in breast318, head and neck319, and ovarian320 cancer cell lines. In 
addition, HK inhibitor lonidamine has been also tested in clinical trials for combinatory 
treatment and showed promising results in ovarian cancer clinical trial321. The glycolytic shift 
can also be switched by leading pyruvate into mitochondria to reinforce the typical phenotype 
of non-malignant cells. This could be facilitated by downregulation of LDHA or by pyruvate 
dehydrogenase kinase (PDK) inhibitors, for example, PDK1 inhibitor dichloroacetate 
(DCA)322-324. For instance, the LDHA inhibitor FX11 suppresses aerobic glycolysis and 
thereby proliferation of NB cell lines325. 
Some drugs can equally effectively inhibit glycolysis and OXPHOS resulting in better outcome 
than single targeted medications. For example, bezielle (BZL101) that is in clinical trials for 
advanced breast cancer326,327. In addition, 3-bromopyruvate (3-BrP) suppresses ATP 
production by inhibiting HK, glycolytic glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
enzymes, and OXPHOS. The combined targets of 3-BrP result in promising results in hepatic 
and pancreatic cancers328. Moreover, the 3-BrP has demonstrated even better results when used 
together with other inhibitors (e.g., rapamycin329,330) or cytotoxic drugs (e.g., platinum-based 
agents331 and doxorubicin332) for NB, leukemia, breast, lymphatic, colon, and hepatic cancers. 
To decrease the 3-BrPA effect to healthy cells, an adjusted form of 3-BrP named 3-bromo-2-
oxopropionate-1-propyl ester has been developed that has showed potent effect on GLUT1- 
and MKI67-expressing NB cells333. 
1.6.2 Glutamine dependency 
Many tumors show signs of increased glucose metabolism or glutamine dependency (Figure 
4), regardless of the fact that glutamine is a non-essential amino acid that can be synthetized 
from glucose. Glutamine is the highest concentrated amino acid in plasma and cancer cells 
utilize it more than any other amino acid.334-336 Amide nitrogen from glutamine is used in 
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nucleotide and amino acid synthesis and carbons in GSH, amino acid, and lipid synthesis. 
Glutamine and its metabolites are known to regulate cellular energy status, redox state, cell 
signaling, nucleotide and amino acid synthesis. For instance, glutamine is important for the 
regulation of oxidative stress in the cell, by being used as a precursor for GSH synthesis. Thus, 
tumor cells fast proliferation and better survival in challenging environments is supported by 
glutamine administration.337-339 Based on the aforementioned FDG-PET tumor detection 
method, glutamine based tracers are also tested in preclinical and early clinical studies340,341. 
This approach gives crucial information about cancers in difficultly analyzed heavy glucose 
consumption sites, such as the brain, and tumors that use glutamine as their primal energy 
source instead of glucose. 
In cancer, stimulation of glutaminolysis is mainly induced by MYC in low glucose and oxygen 
conditions. Increase in glutamine uptake is achieved by higher expression of glutamine 
transporters (SLC1A5, SLC5A1, SLC7A1, SLC7A25) and glutaminases (GLS1/2). 
Mammalian cells have two types of GLS, kidney-type (GLS1) and liver-type (GLS2), that 
catalyze the transformation of glutamine to glutamate and ammonia.342-344 Glutamate can be 
additionally deaminated by GDH, such as GLUD1, into α-ketoglutarate (αKG), which can be 
used to maintain the TCA cycle and biosynthesis. Glutamate can also be transaminated by 
aminotransferases (GOT1/2, GPT), which results in the synthesis of other amino acids, such as 
aspartate and proline.345,346 It has been shown that glutamine addiction by tumor cells is 
diminished after MYC knockdown344. In addition, glutamine deprivation can result in cell death 
of glutamine-dependent cells, whereas administration of oxaloacetate, pyruvate, and αKG 
instead of glutamine can avoid cell death, proposing that MYC-driven glutamine consumption 
is the one providing the TCA cycle with carbon source347,348. Therefore, MYC-driven tumors 
and their glutamine metabolism could be targeted to increase the efficacy of cancer therapy.  
Glutamine depletion will lead to the activating transcription factor 4 (ATF4)-dependent, but 
p53-independent, apoptosis via activation of expression of the pro-apoptotic BCL-2 family 
proteins PUMA and NOXA. Due to this peculiarity, simultaneous treatment with ATF4 
agonists and glutaminolysis inhibitors will cause apoptosis activation and reduction of NB 
tumor size.347 The GLS1 inhibitors, such as small molecule 986 and bis-2-[5-phenylacetamido-
1,2,4-thiadiazol-2-yl] ethyl sulfide (BPTES), suppress MYC-overexpressing tumor cell growth 
migration, invasion, and resistance to oxidative stress349-352. Although, MYCN‒amplified NB 
cells with overly excessive GLS2 expression may be less susceptible to this approach347,349. In 
addition, glutamate dehydrogenase (epigallocatechin-3-gallate (EGCG)) or aminotransferase 
(aminooxyacetate (AOA)) inhibitors are used for consecutive suppression of glutamate 
processing353-355. However, determining the predominant glutamine metabolism pathway for 
the particular tumor makes it challenging to anticipate the cancer cells response to these drugs. 
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2 AIMS 
 
The main goal of this PhD study project was to find strategies for treatment resistant NB cells 
elimination. Considering the importance of mitochondria in apoptosis, the specific goal was to 
explore mitochondrial targeting to enhance anti-tumor treatment efficiency. In addition, our 
aim was to evaluate the role of MYCN expression in NB treatment and to study promising 
strategies to remove treatment resistant NB cells. Furthermore, another aim of this study was 
to understand the mechanisms of NB cell resistance and how to sensitize cells to therapy. The 
results of the research were summarized as following individual papers. 
 
Paper I – In this study, conventionally used chemotherapeutic drug cisplatin was applied in 
combination with the mitochondrial Complex II inhibitor TTFA to investigate whether 
mitochondrial destabilization by TTFA can sensitize NB cells to anti-cancer drugs 
Paper II – Here we evaluated the direct effect of widely used therapeutic drugs on 
mitochondrial activity in combination with glutamine withdrawal, and the possible apoptotic 
effects of such interaction 
Paper III – This article investigated how glutamine deprivation affects NB cell lines response 
to generally used chemotherapeutic drugs 
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3 MATERIALS AND METHODS 
Methods used in constituent papers are briefly described in following paragraphs, however, in 
detail protocols can be found in the papers. 
3.1 HUMAN CELL LINES 
All cell lines used in this study, if not stated otherwise, were cultured in 37 oC humidified 
air/CO2 (5%) atmosphere.  Complete RPMI 1640 (Sigma) medium including heat-inactivated 
fetal calf serum (FBS) 10% (w/v), and penicillin/streptomycin (P/S) (100 U/ml) was used. The 
HCT116 cell line was grown in DMEM (Gibco®) complete medium. For TET21/N cells, 100 
μg/ml hygromycin B (HygroB), and 200 μg/ml geneticin were added to the medium. In 
addition, when needed, the MYCN expression of the TET21/N cells was switched off by 
adding 0.1 μg/ml doxycycline to the cell culture medium. Glutamine deprivation was achieved 
by changing the regular medium to glutamine-free RPMI 1640 24 h prior to treatment. The 
used cell lines and their specifics is summarized in Table 2. 
Table 2. Studied cell lines and their specifics 
Cell line Origin Culture 
medium 
Additions to 
medium 
MYCN status P53 status 
TET21/N 
(MYCN+) 
NB RPMI 1640  FBS 
 P/S 
 geneticin 
 HygroB 
transfected with 
over-expressing 
MYCN 
WT 
TET21/N 
(MYCN‒) 
NB RPMI 1640  FBS 
 P/S 
 geneticin 
 HygroB 
 doxycycline 
downregulated by 
doxycycline 
WT 
SK-N-BE(2) NB RPMI 1640  FBS 
 P/S 
amplification mutated 
IMR-32 NB RPMI 1640  FBS 
 P/S 
amplification WT 
SK-N-AS NB RPMI 1640  FBS 
 P/S 
single copy mutated 
SH-SY5Y NB RPMI 1640  FBS 
 P/S 
single copy WT 
SK-N-SH NB RPMI 1640  FBS 
 P/S 
single copy WT 
HCT116 colon 
cancer 
DMEM  FBS 
 P/S 
single copy WT 
 
3.2 WESTERN BLOT ANALYSIS 
The western blot technique is also known as immunoblotting. It is used to detect proteins of 
interest in a lyzed tissue or cellular sample. Denatured proteins are separated by electrophoresis 
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and incubated with primary antibodies recognizing the protein of interest. Secondary antibodies 
are used for the protein visualization via immunofluorescence or chemiluminescence.  
For the thesis research, the samples were collected by directly adding trypsin to the cells 
adhered to the cell culture dish. Detached cells were collected and centrifuged at 1000 rpm for 
5 min, followed by supernatant removal, and resuspended in phosphate-buffered saline (PBS). 
Protein concentration of collected samples was assessed by Pierce bicinchoninic acid (BCA) 
colorimetric assay and measured by VersaMax™ microplate reader. 
Samples for western blot were mixed with 5x Laemmli’s loading buffer and boiled for 10 min. 
Thereafter, samples were loaded into a 10-15% sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) to be separated by their molecular weight. Separated proteins 
were electroblotted (1.5 h at 120 V) to a nitrocellulose membrane, followed by blocking in 5% 
non-fat milk in PBS (1 h at room temperature) and washing in PBS (3x, 10 min). The 
membranes were incubated with primary antibodies overnight at 4 oC. The following day, 
rinsed membranes were incubated with secondary antibodies (1.5 h, 1:7000). The proteins were 
visualized by Licor® Odyssey® CLx Imaging System or X-ray film. 
3.3 EVALUATION OF APOPTOSIS 
3.3.1 Caspase activation 
3.3.1.1 Caspase processing and specific substrate cleavage 
In normal cells, caspases are in an inactive pro-caspase form and become activated after 
specific signaling. Apoptotic signaling-induced caspase processing includes 
dimerization/oligomerization of pro-caspases and subsequent cleavage into associated small 
and large subunit. The active caspase is then able to cleave its substrates. In this thesis, the 
processing of caspase-3, caspase-8, and caspase-9 was analyzed by Western Blot and specific 
antibodies. In addition, activity of caspases can be studied through detecting cleavage of the 
fluorogenic or chromogenic substrates. For example, poly(ADP-ribose) polymerase (PARP) is 
a target of the caspase-3 and detection of cleavage of PARP is considered as a sign of apoptotic 
cell death. 
3.3.1.2 Fluorometric caspase activity assay 
Caspase activity can be also measured by a fast and easy assay. This method uses different 
substrates that are specific to each caspase to indicate apoptotic activity. These caspase specific 
peptides are conjugated with fluorogenic [7‐amino‐4‐methylcoumarin (AMC)] or chromogenic 
(p‐nitroaniline) groups and added to the lyzed samples. In case of caspase activation, the 
substrates are cleaved and the fluorogenic agent is released. This can be detected by fluorimeter 
or a fluorescence microtiter plate reader, which excites samples at 360 nm and detects emitted 
green 450 nm fluorescence.  
Besides specific substrates, different caspases also need specific buffer conditions. For 
example, optimal pH for caspase activity is between 6.5 and 8, which is achieved by 0.1 M 4-
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(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer. However, 0.1 M 2-(N-
morpholino)ethanesulfonic acid (MES) buffer is more suitable for caspase-2 and caspase-9. 
Reaction buffers also contain stabilizing agents (sucrose), detergents for cell lysis (3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) and/or NP-40) and 
reducing agents, such as dithiothreitol (DTT). In addition, caspase-6 and caspase-7 activity is 
improved in the presence of 0.2 M NaCl and 5 mM Ca2+.  
3.3.2 OMM permeabilization and release of cytochrome c 
OMM permeabilization and cytochrome c release, also known as the “point of no return” in 
apoptosis, can be detected using digitonin-permeabilized samples. Fractionation buffer 
contains 150 mM KCl, 1 mM MgCl2, 0.2 mM ethylene glycol-bis(β-aminoethyl ether)-
N,N,N′,N′-tetraacetic acid (EGTA), 0.05% digitonin, and 5 mM Tris. After 15 min of 
incubation at room temperature, samples are centrifuged at 13,400 rpm for 5 min. Thereafter 
supernatant and pellet are separated, Laemmli’s buffer is added and release of cytochrome c is 
detected by the aforementioned western blotting technique. 
3.4 ASSESSMENT OF OXIDATIVE STRESS 
3.4.1 Mitochondrial ROS 
Mitochondria are considered the main source of ROS, which in excessive amounts can lead to 
apoptotic cell death. Mitochondrial superoxide can be measured in live cells by using 
MitoSOX™ Red (Molecular Probes®) dye that due to is positive charge locates into 
mitochondria. The dye reacts with superoxide and the oxidized product absorbs 510 nm and 
emits 580 nm light. In all of the papers, BD Accuri™ C6 flow cytometer was used to analyze 
the percentage of MitoSOX-positive cells and the signal strength. In addition, in the Paper I 
Zeiss LSM 510 META confocal laser scanning microscope (Zeiss Jena, Germany) was used 
for time-lapse experiments. For this purpose, cells were grown and treated in the POC-R cell 
cultivation system (Zeiss, Jena, Germany) at 37 °C and humidified air/CO2 (5%) atmosphere.  
3.4.2 Content of SH groups 
The sulfhydryl (SH) groups are part of cellular antioxidant system. Measuring the content of 
SH groups gives information about cells ability to resist oxidative stress. In Paper II and III, 
amount of SH groups was measured using Ellman's reagent (5,5'-dithiobis-(2-nitrobenzoic 
acid) or DTNB). Collected cells were resuspended in Tris buffer (150 mM, pH 8.2) and divided 
into two separate samples, allowing assessment of the total and soluble SH groups of the same 
sample. After addition of DTNB and incubation for 30 min, samples absorbance was measured 
at 412 nm using a VersaMax™ microplate reader.   
3.5 MEASUREMENT OF MITOCHONDRIAL OXYGEN CONSUMPTION 
Measurements of oxygen consumption provide information about mitochondrial intactness and 
how the drugs affect ETC. In Paper I and II, oxygen electrode (Hansatech Instruments, Norfolk, 
UK) and OxygraphPlus software (Hansatech Instruments, Norfolk, UK) were used for oxygen 
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consumption assessment. Cells were collected and resuspended in 0.01% digitonin 
supplemented KCl-based buffer. Assessment of the activity of different complexes was 
performed using digitonin-permeabilized cells, to allow accessibility of exogenous substrates 
to mitochondria. At first, basal respiration was measured, followed by addition of chemicals of 
interest. Respiratory activity of separate respiratory complexes and rate of maximum 
respiration were analyzed using specific mitochondrial substrates and inhibitors. For example, 
pyruvate and malate support Complex I respiration, and succinate Complex II activity. Specific 
inhibitors, such as rotenone (Complex I), antimycin A (Complex III), and oligomycin (ATP 
synthase), can also be used to get information about complexes of interest. The rate of 
maximum respiration can be measured after adding the uncoupling agent carbonyl cyanide m-
chloro phenyl hydrazine (CCCP).  
In Paper II, besides oxygraph, respiration studies were also conducted using Seahorse Analyser, 
which allows assessment of oxygen consumption of attached cells in their normal environment 
on 96 well plate. Typical Seahorse assay is as follows. Initially, baseline cellular oxygen 
consumption rate (OCR) is measured, which consists of basal and non-mitochondrial 
respiration. Thereafter, ATP synthase inhibitor oligomycin is added to detect ATP-linked 
respiration and proton leak. After that, the uncoupler CCCP is injected to measure maximal 
respiratory capacity and then antimycin A and rotenone to shut down ETC and to analyze non-
mitochondrial respiration. The oxygraph and Seahorse Analyser data was normalized by either 
cell number or protein concentration. 
3.6 MEASUREMENT OF MITOCHONDRIAL TRANSMEMBRANE POTENTIAL 
(ΔΨm) 
The ΔΨm plays a central role in aerobic energy production and other mitochondrial processes, 
such as Ca2+ accumulation or protein import. The proton gradient is a result of ETC activity 
and is in turn used for ATP production, therefore, changes in the ΔΨm can affect vital 
mitochondrial functions. Cationic mitochondria-accumulating fluorescent probes, such as 
tetramethylrhodamine ethyl ester (TMRE), can be used to measure ΔΨm of intact cells. 
3.7 MEASUREMENT OF ALTERATIONS IN CYTOSOLIC Ca2+ 
The Ca2+ is part of cellular signaling and regulate the activity of several enzymes, proteins, and 
ion channels. Sudden increase of cytosolic Ca2+ can trigger its accumulation in mitochondria 
with subsequent rupture of the mitochondrial membrane, due to the stimulation of MPTP, and 
cell death activation. Cytosolic calcium levels can be analyzed using the live cell-permeable 
calcium-sensitive fluorescent dye Fluo-4AM (Invitrogen-Molecular Probes, Eugene) and flow 
cytometer or fluorescent microscope.  
3.8 STATISTICS 
All the data presented in this thesis are the average of at least three separate repetitive 
experiments. The error bars represent standard deviation and the statistical significance was 
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evaluated using Student’s t-Test (two-tailed distribution, two-sample unequal variance) or two-
way ANOVA (*p < 0.05 and **p < 0.01). 
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4 SUMMARY OF THE PAPERS 
PAPER I 
 
Kruspig B, Valter K, Skender B, Zhivotovsky B, Gogvadze V (2016).  
Targeting succinate:ubiquinone reductase potentiates the efficacy of anticancer therapy.  
Biochimica et Biophysica Acta, 1863: 2065-2071 
 
Mitochondria are one of the central elements of apoptosis because the release of pro-apoptotic 
proteins from the intermembrane space of mitochondria into cytosol is considered as a “point 
of no return”. The release of cytochrome c can be stimulated by compounds specifically 
destabilizing mitochondria, such as inhibitors of mitochondrial respiratory complexes. 
Blocking respiratory complexes stimulates electron leakage with formation of ROS, which 
contribute to OMM permeabilization. DNA damaging alkylating agents, such as cisplatin, can 
lose their therapeutic effect due to the development of resistance. Therefore, increasing the 
cytotoxic efficacy of cisplatin by co-administering a mitochondrial drug can lead to a better 
treatment outcome. The aim of this paper was to investigate whether mitochondrial 
destabilization by the mitochondrial Complex II inhibitor TTFA can potentiate the therapeutic 
effectiveness of cisplatin on a panel of NB cell lines. 
In this paper, NB cell lines with different sensitivity towards therapy were used. The effect of 
the co-administration was analyzed by assessment of mitochondrial function and various 
apoptotic markers. Our results revealed how simultaneous administration of non-toxic dose of 
succinate dehydrogenase (SDH) ubiquinone-binding site inhibitor TTFA and harmless dose of 
cisplatin stimulated cell death in several NB cell lines in a synergistic manner. Further studies 
revealed that the TTFA-induced mitochondrial ROS production is the underlying mechanism 
of sensitization to cisplatin treatment. Excessive ROS production led to the permeabilization 
of the OMM, release of cytochrome c, processing and activation of caspase-3, and cleavage of 
PARP; all markers of an apoptotic cell death. Furthermore, experiments with methyl malonate, 
an inhibitor of the SDHA subunit, suppressed TTFA-stimulated apoptosis, indicating that 
TTFA’s chemosensitizing effect requires oxidation of succinate. 
However, co-administration of TTFA and cisplatin to IMR-32 NB cells had contrasting effects, 
resulting in suppressed apoptosis. Studies on IMR-32 Complex II revealed its impaired activity, 
explaining the unexpected outcome. Therefore, fully active SDH is a prerequisite for TTFA-
induced sensitization of NB cells to treatment with cisplatin. In conclusion, these findings show 
the potential use of TTFA as an adjuvant to improve cisplatin treatment of specific types of 
NB. 
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PAPER II 
 
Valter K, Maximchik P, Zhivotovsky B, Gogvadze V.  
Distinct effects of etoposide on glutamine-addicted neuroblastoma.  
(manuscript, submitted) 
 
Tumor cell elimination through stimulation of mitochondrial apoptotic pathways is a promising 
strategy. Compounds that target mitochondria can suppress mitochondrial activity or contribute 
to the outer mitochondrial membrane permeabilization leading to apoptosis. Conventionally 
used chemotherapeutic drugs are DNA-damaging agents but their ability to directly target 
mitochondria is unknown. In addition, some tumors display addiction to glutamine, a substrate 
for antioxidant GSH, despite the fact that it is a nonessential amino acid. A subset of highly 
aggressive cases of NBs is characterized by high MYCN expression, which in turn regulates 
cellular metabolism, including glutaminolysis. Our aim was to reveal whether 
chemotherapeutic drugs affect mitochondrial activity, and if this can contribute to apoptosis 
initiation. 
Our results showed that among tested therapeutic drugs, only etoposide caused a rapid decrease 
in oxygen consumption. Although, the inhibition of respiration was reversible and restored in 
a time- and concentration-dependent manner. Further studies demonstrated a severe 
suppression of Complex I after adding etoposide, whereas no immediate effect of the drug on 
Complex II was detected. The assessment of respiration after 6 h and 18 h etoposide treatment 
revealed that Complex I activity has recovered to normal level. Blocking the Complex I can 
cause a leakage of electrons and formation of ROS. Hence, the assessment of mitochondrial 
superoxide production upon etoposide administration was performed, revealing sudden ROS 
formation. However, we could not detect strong markers of apoptosis, they arose only after 
glutamine withdrawal and subsequent attenuation of the level of GSH. Therefore, simultaneous 
stimulation of mitochondrial ROS production and removal of the antioxidant GSH can lead to 
the destabilization of mitochondria and subsequent cytochrome c release and apoptosis 
activation. In addition, after 24 hours, apoptosis was stimulated via p53-dependent, BID-
mediated pathway. The outcome of the treatment with etoposide, hence, will be dependent on 
the balance between these two processes. 
In conclusion, DNA targeting etoposide also interacts and inhibits mitochondrial ETC 
Complex I that can induce cell death via electron leakage and ROS production. At the same 
time, mitochondrial antioxidant defense system is removing the excess ROS and rescues cells 
from controlled cell death. Thus, glutamine removal and subsequent depletion of antioxidants 
can make targeting mitochondria more efficient, enhance and strengthen anti-tumor therapy. 
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PAPER III 
 
Valter K, Chen L, Kruspig B, Maximchik P, Cui H, Zhivotovsky B, Gogvadze V (2017).  
Contrasting effects of glutamine deprivation on apoptosis induced by conventionally used 
anticancer drugs.  
Biochimica et Biophysica Acta, 1864: 498-506 
 
Targeting energy-producing pathways is a promising approach for cell death stimulation and 
cancer cell elimination. In addition to the glycolytic switch (Warburg effect), various tumors 
show glutamine dependence even though it is a non-essential amino acid that can be produced 
from glucose. Attained glutamine is converted by glutaminase into glutamate, which is used as 
an important pre-substrate for the Krebs cycle, synthesis of GSH, amino and fatty acids to 
support intensive proliferation of cancer cells. One of such glutamine-dependent tumors is NB, 
most common solid cancer in childhood. Therefore, specific targeting of cancer cells’ 
glutaminase or withdrawal of glutamine could be a promising therapeutic strategy to enhance 
the efficiency of NB treatment and overcome drug-resistance. The aim of this work was to 
study changes in the cellular response to chemotherapeutic drugs under glutamine deprivation.   
This was achieved by growing cells in a glutamine-supplemented or glutamine-free medium 
24 h prior treatment with cisplatin or etoposide. We found that depending on the drug, 
glutamine deprivation can lead to contrasting cellular responses. The withdrawal of glutamine 
consistently suppressed etoposide-induced but stimulated cisplatin-induced apoptosis, thereby 
exposing a promising strategy for the elimination of otherwise resistant tumor cells. Further 
analysis revealed that suppression of etoposide-induced cell death correlated with an 
attenuation of p53, which regulates the expression of various pro-apoptotic BCL-2 family 
proteins. However, increase in cisplatin-induced apoptosis was due to the ROS-mediated 
downregulation of FLIP-S, a caspase-8 inhibitor, which in turn allowed caspase-8 activation 
and apoptotic cell death. 
Therefore, tumor cells can be sensitized to therapy by suppressing glutamine metabolism; 
although, the possibility of unfavorable effects due to the specific anti-cancer drug should be 
considered. 
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5 DISCUSSION 
Cancer and apoptosis are known as antagonistic processes and, therefore, stimulation of 
apoptosis is the main strategy in cancer therapy. However, defects of the apoptotic pathways 
can make cells treatment-resistant.3 Hence, more specific and effective approaches of cancer 
cell targeting are being developed to achieve better outcome. For example, mitochondrion, one 
of the key player of apoptosis, represents an intriguing target for therapy improvement. Besides 
regulating apoptosis, mitochondria also coordinate cellular metabolism, redox status, Ca2+ 
homeostasis etc making them appropriate targets for cancer cell elimination.193-195,356 
To overcome treatment resistance and severe side effects, sensitizing cells and their 
mitochondria with adjuvant chemicals to chemotherapeutic drugs is a promising approach. The 
aim of the Paper I was to study whether the ETC Complex II inhibitor TTFA, more specifically 
SDH ubiquinone-binding site inhibitor, can sensitize a panel of NB cell lines with different 
sensitivity for clinically used anti-cancer drug cisplatin. Our results demonstrated that TTFA 
can potentiate the effect of cisplatin in all the NB cell lines, which have a functional succinate 
oxidation. 
Neuroblastoma is the most common extracranial solid tumor in childhood and a subset of 
highly aggressive NBs are known for their MYCN oncogene amplifications33,42,43. In addition, 
MYCN regulates mitochondrial biogenesis and probably can modulate mitochondrial stability 
in the cell. Therefore, cell lines with different MYCN expression were analyzed. The SK-N-
BE(2) and SK-N-AS were included as highly resistant cell lines due to their mutations in p53 
and the epigenetic loss of caspase-8 in SK-N-BE(2). The TET21/N cell line is transfected with 
overexpressing MYCN and represents a cell line with medium response to treatment. In 
addition, the IMR-32 cell line was chosen for its high sensitivity to anti-cancer drugs.357,358 In 
almost all of the tested NB cell lines, TTFA enhanced the apoptotic effect of cisplatin. 
Importantly, both TTFA and cisplatin were used in concentrations that by itself did not cause 
any or very little toxicity to the cells. Upon co-treatment, reduced concentrations give the 
possibility to decrease the occurrence of side effects, at the same time achieving better results. 
Based on the results, we revealed, as expected, that the increased cell death was due to the 
mitochondrial instability, primarily caused by TTFA action on ETC Complex II. The TTFA 
caused leakage of electrons from Complex II resulting in excessive mitochondrial ROS 
production that contributed clearly to the increase in cell death. It has been shown previously 
that mainly Complexes I and III are the sites of ROS production254,255. However recent 
publications, including ours, demonstrated that inhibition of Complex II, especially its 
ubiquinone-binding site, also leads to ROS formation252,253. The sensitization effect vanished 
in the presence of antioxidant N-acetylcysteine (NAC), confirming the importance of ROS 
activity in apoptosis induction. Oxidative stress can trigger MPTP opening359 and oxidization 
of the cytochrome c anchor cardiolipin360, leading to cytochrome c release and apoptosis 
activation. It is worth noting that for stimulation of the cell death by TTFA, the cells should be 
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able to oxidize succinate, since, suppression of SDH subunit A, responsible for conversion of 
succinate into fumarate, repressed stimulation. 
However, this effect was not seen in every cell line; the IMR-32 was the only tested cell line, 
in which apoptosis was not stimulated after TTFA treatment. This finding was unexpected 
because the IMR-32 cell line itself is very responsive to treatment and 10 times lower 
concentration of cisplatin had to be used in order to study the mechanism. The analysis of IMR-
32 Complex II ability to oxidize succinate revealed its impaired function, explaining the 
unpredicted effect of TTFA. Some tumors have mutations in SDH, which leads to the 
accumulation of succinate and thereby support resistance of Complex II targeting. Therefore, 
prior knowledge about oxygen consumption and possible mutations in tumor cell ETC are 
crucial for beneficial outcome. Thus, suppression of various complexes of the respiratory chain 
is a promising strategy for anti-tumor therapy but further studies should be conducted to 
determine its safety and other potential targets. 
Generally, anti-cancer drugs damage nuclear DNA, which leads to the activation of p53 and 
pro-apoptotic factors. Although, DNA might not be the only target of chemotherapeutic drugs 
and secondary targets play an important role in treatment efficiency and safety. For example, 
DNA-targeting drugs can affect mitochondria. This information can be crucial to understand 
the treatment outcome, increase its efficiency, and decrease side effects. Our aim of Paper II 
was to expand our knowledge about the effects of anti-cancer drugs on mitochondria and its 
consequences on treatment. To our surprise, among several anti-tumor drugs, only etoposide 
had a direct and strong effect on mitochondria. We found that upon addition of etoposide, there 
was a sudden stop in Complex I activity, which led to the electron leakage and ROS formation. 
However, it was not enough to induce apoptosis after 6 h of treatment; cell death at this early 
time point was only detected upon removal of glutamine and stimulation of oxidative stress. 
Excessive ROS production is an important part of anti-tumor strategy and many drugs are 
developed to target mitochondria. Although, cancer cells also have mechanisms to remove 
ROS and thereby reduce oxidative stress caused damage. They have high levels of ROS-
detoxifying enzymes to avoid cell death activation.361 Tumor cells ability to remove ROS can 
be in turn affected by reducing activity of their antioxidant machinery. For example, reduction 
of water- and lipid-soluble antioxidant content, such as GSH, supports ROS accumulation, 
which can cause toxicity and apoptosis. 
Glutathione is part of glutamine metabolism that is in turn regulated by MYCN oncogene. The 
MYCN regulates the expression and activity of the glutaminase, which converts glutamine into 
glutamate, a precursor of GSH.344 MYC is also a regulator of cell proliferation, differentiation, 
apoptosis, and stimulates mitochondrial biogenesis and function301. Thus, targeting MYCN 
activity and functions is an appealing strategy for tumor cell elimination. The MYCN regulated 
metabolism can be affected by glutamine withdrawal, making cells more susceptible to cell 
death. As expected, our data with etoposide treated and glutamine deprived cells showed a 
significant increase in apoptosis after 6 h of treatment. However, this effect was reduced after 
24 h of treatment, suggesting the existence of different mechanisms activated at different time-
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points. More specifically, 6 h etoposide treatment does not affect the level of full-length BID 
but after 24 h cleavage of BID is detected. Therefore, at early time-points, etoposide triggered 
suppression of Complex I and ROS production are the main activators of apoptosis, although, 
after 24 h, p53 and BID activation are responsible for apoptotic cell death. 
Downregulation of MYCN in NB could reduce the level of glutaminase and consequently 
GSH, making cells even more sensitive to oxidative stress. However, our results did not reveal 
any attenuation of glutaminase content nor GSH depletion after MYCN downregulation nor 
glutamine depletion. Furthermore, MYCN low expressing cells were more resistant to 
etoposide treatment. This can be explained by the low basal level of p53 in MYCN‒ cells that 
attenuates cells response to DNA damage. In addition, lower levels of full-length BID were 
also detected in MYCN‒ cells. All contributing to the lower apoptotic response to treatment 
than MYCN+ cells. 
Regardless of aforementioned shortcomings, lack of MYCN did not affect etoposide effect on 
Complex I. Moreover, as with MYCN+ cells, removal of glutamine stimulated apoptotic cell 
death after 6 h of treatment. Furthermore, the increase in apoptosis was almost twice as high as 
with MYCN+ cells. This revealed a promising strategy to overcome MYCN‒ cell resistance to 
treatment. Even though there was also a decrease of apoptosis detected after 24 h, it was still 
higher than with etoposide alone and the reduction was not as prominent as in MYCN+ cells. 
 
Figure 5. Schematic representation of possible pathways involving etoposide treatment and glutamine deprivation 
in TET21/N cells. Etoposide has an immediate effect (black arrows) on mitochondrial respiratory chain Complex 
I that will cause ROS production, cytochrome c release and modest apoptosis induction. This effect can be 
increased by glutamine deprivation (dashed arrows). Long-term (24h) etoposide treatment (dotted arrows) will, 
however, cause DNA damage-dependent p53 expression and mitochondrial apoptosis activation. OMM – outer 
mitochondrial membrane; IMM – inner mitochondrial membrane  
 
In conclusion, etoposide-caused apoptosis is a complex process that involves activation of 
various pathways at different time points. We discovered that besides DNA damage, 
subsequent stabilization of p53, and apoptosis activation, etoposide also suppresses ETC 
Complex I activity. This will lead to electron leakage from ETC and formation of ROS. 
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However, the cellular antioxidant defense systems are very efficient in removing all the excess 
ROS and thereby avoiding cell death. This can be prevented by reducing the level of cellular 
antioxidants, for example, by glutamine withdrawal that leads to the reduction of GSH and the 
increase in ROS levels leading to apoptosis induction. A scheme representing the possible 
pathways involved in apoptosis stimulation in our experimental model is shown in Figure 5. 
Altogether, relative contribution of oxidative stress and p53 expression determine the outcome 
of the treatment. Therefore, depletion of antioxidants or inhibition of pathways responsible for 
cellular antioxidant response can be used to improve tumor treatment. 
Metabolism of GSH is an important part of many cancer cells existence and targeting this 
peculiarity has been an appealing approach for tumor elimination352,362. In Paper III we 
investigated the effect of glutamine removal to conventionally used anti-cancer drug treatment 
on NB cell lines. To our surprise, depending on the anti-tumor drug, glutamine deprivation had 
contrasting effects. Glutamine withdrawal increased cisplatin-induced cell death but decreased 
apoptotic response to etoposide, thereby demonstrating an activation of different pathways. 
Etoposide and cisplatin are chemotherapeutic drugs that target DNA and stimulate p53 
expression. We also detected this in NB cells after etoposide treatment, which led to the 
expression of p53, DR5, caspase-8 processing, and induction of apoptosis. Although, when 
glutamine was removed before etoposide treatment adverse effects were seen. Upon treatment 
with etoposide, removal of glutamine prevented upregulation of p53, DR5 expression, and 
caspase-8 processing, resulting in suppression of cell death. Transcription factor p53 seems to 
be the main upstream regulator of the process. Besides regulating DR5, p53 can also activate 
other pro-apoptotic genes, such as BID, BAX, and NOXA or PUMA, that facilitate OMM 
permeabilization, cytochrome c release and apoptotic cell death138,363,364. Hence, 
aforementioned downregulation of p53 can be the reason of apoptosis suppression. However, 
the connection between glutamine deprivation, etoposide treatment, and p53 is not clear yet 
and further studies should be conducted to better understand the link. 
In case of cisplatin, contrary, glutamine withdrawal further stimulated p53 and DR5 expression. 
Furthermore, cisplatin is also known to produce ROS365. The ROS formation analysis revealed 
that low dose of cisplatin had a modest effect on ROS production, whereas, removal of 
glutamine together with cisplatin treatment strongly stimulated formation of ROS. This can be 
explained by the role of glutamine as a precursor for the antioxidant GSH, therefore, the lack 
of glutamine results in GSH depletion and increased ROS levels. This was also confirmed by 
experiments with GSH synthesis inhibitor BSO that had the same effect on the consequences 
of cisplatin treatment as glutamine removal. The ROS regulates many cellular processes by 
effecting enzyme activity. Our analysis revealed ROS-facilitated attenuation of protein kinase 
Akt, phosphorylated Akt, and its target FLIP-S, a caspase-8 inhibitor. Subsequently, the 
activity of caspase-8 was elevated stimulating apoptotic cell death. Based on these results, the 
DR5 upregulation and ROS-induced FLIP-S downregulation are both contributing to the 
caspase-8 activation, which induces apoptosis via mitochondrial BID-mediated pathway 
followed by apoptosome formation, caspase-9 processing and activation of caspase-3. 
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Furthermore, the significance of caspase-8 activity for apoptosis stimulation upon glutamine 
withdrawal in cisplatin-treated NB cells was confirmed by using caspase-8 deficient SK-N-
BE(2) cell line. The described increase in cell death in TET21/N cells upon glutamine 
withdrawal was not detected in SK-N-BE(2) cells, in which caspase-8 gene in epigenetically 
silenced. 
 
Figure 6. Glutamine withdrawal alters apoptotic response in etoposide or cisplatin treated cells. Withdrawal of 
glutamine abrogates p53 stabilization in etoposide-treated cells (A). Consequently, DR5 is downregulated, 
processing of caspase-8 is suppressed and cleavage of BID is attenuated (B). Subsequently, OMM is stabilized 
towards permeabilization (C). This leads to prevention of caspase-9 processing and inhibition of caspase-3 activity 
and cell death (D). In case of cisplatin glutamine withdrawal leads to glutathione depletion and stimulation of ROS 
production (E) causing the suppression of Akt pathway (F). As a result, the level of FLIP-S declines (G), caspase-
8 is activated causing cleavage of BID, OMM permeabilization, release of cytochrome c, processing of caspase-
9, activation of caspase-3, and cell death (I). 
 
The scheme illustrating the ongoing mechanism in NB cells after glutamine removal and 
treatment with etoposide or cisplatin is shown in Figure 6. In conclusion, two separate 
pathways are activated depending on the anti-cancer drugs. Glutamine deprivation suppresses 
etoposide-induced apoptosis via downregulation of p53 and subsequent events. In contrast, 
glutamine withdrawal increases cisplatin-induced cell death via rise in ROS production and 
caspase-8 activity. Taken together, targeting glutamine metabolism is a promising approach for 
treatment improvement, especially in case on cisplatin, where lowering the doses means 
decreased side effects. However, glutamine deprivation can also suppress apoptosis, which was 
seen in the case of etoposide. Due to this unexpected outcome, targeting glutaminolysis should 
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be done cautiously. Further research is needed to undercover the exact mechanisms of action 
and to find effective inhibitors of glutamine metabolism. 
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6 CONCLUSIONS AND OUTLOOK 
Induction of apoptosis, as a mode of controlled cell death, is one of the main strategies to 
eliminate cancer cells. Usually, in the process of anti-tumor therapy, apoptosis is activated after 
administration of DNA damaging chemotherapeutic drugs. These chemicals have shown 
promising results, but severe toxicity, side effects, and development of resistance make their 
use challenging. Furthermore, mutations in the apoptotic machinery of cancer cells can 
suppress cell death. Therefore, additional strategies are needed for treatment improvement. One 
approach would be to target different steps of apoptotic pathway to increase the effect of the 
drugs. This can be done, for example, via targeting mitochondria that are known as central 
regulators of apoptosis. Suppression of cellular energy producing pathways was confirmed to 
be a promising strategy for tumor cell elimination. Inhibition of glycolysis317, glutamine 
deprivation366, or targeting mitochondria can contribute to the improvement of anti-tumor 
therapy. 
In this study we analyzed whether in NB cell lines mitochondrial destabilization by the 
mitochondrial ETC Complex II inhibitor TTFA can sensitize cells to alkylating-agent cisplatin. 
We demonstrated how simultaneous use of non-toxic dose of TTFA and low dose of cisplatin 
can result in significant increase ROS production and subsequent activation of apoptotic cell 
death of NB cell lines that have fully functional Complex II. These findings clearly 
demonstrated the potential use of direct mitochondrial targeting as a part of anti-cancer 
strategy. However, the toxicity of TTFA in animal models is still unknown and should be 
studied as a next step towards combined therapy. Furthermore, the TTFA sensitizing effect 
only occurs in functional Complex II cell lines, suggesting the need of preliminary experiments 
before treatment for successful NB therapy. 
Not only specific inhibitors of the mitochondrial respiratory chain, such as TTFA, but also 
DNA damaging drugs can cause similar effects. In this study, we observed an immediate effect 
of certain anti-cancer drugs on NB mitochondria. Obtained results revealed a direct effect of 
etoposide, but not cisplatin or doxorubicin, specifically on Complex I. The activity of Complex 
I was suppressed and facilitated the leakage of electrons, subsequent ROS formation, and 
apoptosis in glutamine deprived conditions. These results show that in some cases, the direct 
effect of anti-tumor drugs on mitochondria should be taken into consideration. The mechanism 
behind etoposide suppression of Complex I is unclear and studies revealing this action could 
increase etoposide efficacy. For example, if etoposides respiratory inhibition could be 
supported and maintained, additional redox manifestations, such as reducing glutamine 
metabolism as used in the study, may not be needed.   
Despite the benefit for anti-tumor treatment, glutamine deprivation should be performed 
cautiously. As we showed, cellular response to various anti-cancer drugs under glutamine 
deprivation revealed contrasting outcomes. Glutamine withdrawal stimulated cisplatin-induced 
apoptosis but suppressed etoposide-induced cell death. To better understand this phenomenon, 
the connection between glutamine removal, drug activity, and p53 expression should be further 
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investigated. In our experiments glutamine deprivation was carried out before addition of the 
drugs, studying the more specific effect of the absence of glutamine on cell metabolism could 
provide us with additional information. Taken together, targeting glutamine metabolism can 
sensitize NB cells to treatment and the development of better inhibitors is a promising strategy 
for tumor cell elimination. However, adverse effects due to the drug action mechanism should 
be taken into consideration. 
In conclusion, this study gained deep understanding about treatment of resistant NB cells lines 
and their mitochondrial stability under conditions of therapeutic targeting. The results of the 
doctoral study improved the knowledge about different MYCN expressing and glutamine 
dependent NB cells lines, giving new possibilities and insight into NB response to treatment. 
Moreover, several approaches for NB cell sensitization to chemotherapeutic drugs were 
revealed, which pave the way for more effective treatment in the future. 
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